Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

Study Overview
=================
Brief Summary
-----------------
In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Official Title
-----------------
The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels

Conditions
-----------------
Psoriasis Vulgaris, Psoriatic Arthritis, Metabolic Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: omentin, visfatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic Patients older than 18 years Patients who accept dermatological and rheumatic examination Patients not receiving systemic treatment related to the disease in the last 1 month Exclusion Criteria: Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis Patients under 18 years Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: psoriasis vulgaris,<br>patients who have only psoriasis vulgaris | Diagnostic Test: omentin, visfatin<br>* diagnostic blood test<br>|
| Other: psoriatic arthritis<br>patients who have psoriatic arthritis | Diagnostic Test: omentin, visfatin<br>* diagnostic blood test<br>|
| Other: healthy control<br>healthy people | Diagnostic Test: omentin, visfatin<br>* diagnostic blood test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| omentin | Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels | 6 months | 
| visfatin | Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psoriasis vulgaris, psoriatic arthritis, metabolic syndrome, omentin, visfatin